Contents of volume 18

No. 1 (pp 1–92) published September 1986
No. 2 (pp 93–184) published November 1986
No. 3 (pp 185–292) published December 1986

This volume contains two supplements

No. 1: 12th Annual Meeting (Abstracts) of the European Society for Medical Oncology Nice, November 28–30, 1986 A1–A80 (316 abstracts)

No. 2: International Symposium on "Recent Experience with Ifosfamide/Mesna in Solid Tumors" Stockholm, June 1985 S1–S58

Aas M → Hall KS, et al. 74
Aas M → Fossa SD, et al. 252
Abe R, Akiyoshi T, Tsuji H, Baba T: Protection of antiproliferative effect of *cis*-diammine-dichloroplatinum (II) by sodium thiosulfate 98
Abel U → Drings P, et al. S 34
Abikhalil F → Dubois J, et al. 226
Aherne GW → Burton NK, et al. 90
Ahmed NK → Vasanthakumar G 105
Aisner J → Tchekmedyian NS, et al. 33
Akiyoshi T → Abe R, et al. 98
Allan SG, Farquhar DF, Harrison DJ, Leonard RCF: Anti-emetic efficacy of dexamthasone in combination for out-patients receiving cytotoxic chemotherapy 86
Anderson H → Thatcher N, et al. S 30
Angelelli B → Camaggi CM, et al. 47
Arasi V → Magrath I, et al. S 25
Arkell DG → Perren TJ, et al. 39
Arrigo P D' → Preisler HD, et al. 257
Atassi G → Dubois J, et al. 226
Athis P d' → Gislain C de, et al. 276
Ayoub J → Bardakji Z, et al. 140

Baba T → Abe R, et al. 98
Bailey LC → Perren TJ, et al. 39
Bakke O → Lundgren S, et al. 270
Ballatori E → Roila F, et al. 88
Bander NH → Sternberg CN, et al. 265
Bardakji, Jolivet J, Langelier Y, Besner J-G, Ayoub J: 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies 140
Barnett MJ → Burton NK, et al. 90
Barnett MJ → Dhaliwal HS, et al. 59
Barnett MJ → Richards MA, et al. 51
Barnett MJ → Waxman JH, et al. 174
Basurto C → Roila F, et al. 88
Beex LVAM → Speth PAJ, et al. 78
Behrens BC → Louie KG, et al. 153
Belle SJP van, de Planque MM, Smith IE, Oosterom AT van, Schoemaker TJ, Deneve W, McVie JG: Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy 27
Bennett J → Preisler HD, et al. 257
Besner J-G → Bardakji Z, et al. 140
Besser GM → Waxman JH, et al. 174
Biran S → Sulkes A, et al. 162
Blackledge G → Bramwell VHC, et al. S 13
Blackledge G → Dombernowsky P, et al. S 17
Blackledge G → Perren TJ, et al. 39
Blumenschein GR → Holmes FA, et al. 157
Boezeman JBM → Speth PAJ, et al. 78
Bogdanovic RP → Brandes LJ, et al. 21
Bologna R → Tonini GP, et al. 92
Bosanquet AG, Clarke HE: Chlorambucil: stability of solutions during preparation and storage 176
Bose R → Brandes LJ, et al. 21
Bosly A → Ceulemans F, et al. 44
Boven E, Nauta MM, Schlüper HMM, Erkelens CAM, Pinedo HM: Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts 124
Bozzino JM → Cantwell BMJ, et al. S 29
Brade W, Seeber S, Herdrich K: Experimental and clinical comparative activity of ifosfamide and cyclophosphamide S 1
Bragman K → Dhaliwal HS, et al. 59
Bramwell VHC, Mouridsen HT, Santoro A, Blackledge G, Somers R, Thomas D, Sylvester R, Van Oosterom AT: Cyclophosphamide versus ifosfamide: Preliminary report of a randomized phase II trial in adult soft tissue sarcomas S 13
Brandes LJ, Bogdanovic RP, Cawker MD, Bose R: The antiproliferative properties of tamoxifen and phenothiazines may be mediated by a unique histamine receptor ($?H_3$) distinct from the calmodulin-binding site 21
Bregmann CL, Williams PD: Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin 117
Brenner DE, Collins JC, Hande KR: The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits 219
Brinkley D → Sriskandan K, et al. 63
Brivet F, Pavlovitch J-M, Gouyette A, Cerrina M-L, Tchernia G, Dormont J: Inefficiency of early prophylactic hemodialysis in *cis*-platinum overdose 183
Brodie MJ → Kerr DJ, et al. 239
Browman G → Preisler HD, et al. 257
Bülzebruck H → Drings P, et al. S 34
Burton NK, Barnett MJ, Aherne GW, Evans J, Douglas I, Lister TA: The effect of food on the oral administration of 6-mercaptopurine 90
Buzdar AU → Holmes FA, et al. 157

Cabanillas F → Danhauser L, et al. 145
Calman FMB → Sriskandan K, et al. 63
Calvert AH → Mbidde EK, et al. 284
Camaggi CM, Strocchi E, Comparsi R, Testoni F, Angelelli B, Pannuti F: Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients 47
Cantwell BMJ, Franks CR, Harris AL: A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma 286
Cantwell BMJ, Harris AL, Bozzino JM: Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancer S 29
Catane R → Sulkes A, et al. 162
Catino JJ, Francher DM, Schurig JE: Evaluation of *cis*-diamminedichloroplatinum(II) combined with metoclopramide or sodium thiosulfate on L1210 leukemia in vitro and in vivo 1
Cawker MD → Brandes LJ, et al. 21
Cerny T, Margison JM, Thatcher N, Wilkinson PM: Bioavailability of ifosfamide in patients with bronchial carcinoma 261
Cerrina M-L → Brivet F, et al. 183
Ceulemans F, Humblet Y, Bosly A, Symann M, Trouet A: A phase I study of vinblastine tryptophan ester 44
Christian E → Klein HO, et al. S 19
Clagett-Carr K → Weiss RB, et al. 185
Clarke HE → Bosanquet AG 176
Clayton RN → Perren TJ, et al. 39
Coerper C → Klein HO, et al. S 19
Cohen BE → Tchekmedyian NS, et al. 33

Coleman RE, Harper PG, Gallagher C, Osborne R, Rankin EM, Silverstone AC, Slevin ML, Souhami RL, Tobias JS, Trask CW, Wiltshaw E: A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix 280
Collins JC → Brenner DE, et al. 219
Community Cancer Oncology Program Investigators → Scher HI, et al. 24
Comparsi R → Camaggi CM, et al. 47
Cornaglia-Ferraris P → Tonini GP, et al. 92
Cottam J → Perren TJ, et al. 39
Crowther D → Wagstaff J, et al. 54
Cummings J → Kerr DJ, et al. 239

Danhauser L, Plunkett W, Keating M, Cabanillas F: 9-β-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma 145
Deneve W → Belle SJP van, et al. 27
Diaz-Rubio E → Martin-Jimenez M 168
Dhaliwal HS, Shannon MS, Barnett MJ, Prentice HG, Bragman K, Malpas JS, Lister TA: Treatment of acute leukaemia with *m*-AMSA in combination with cytosine arabinoside 59
Dombernowsky P, Mouridsen H, Schütte J, Santoro A, Roussé J, Somers R, Stewart W, Pinedo HM, Oosterom AT v, Blackledge G, Thomas D., Sylvester R: Phase II study of ifosfamide + adriamycin in advanced soft tissue sarcoma in adults. A preliminary analysis S 17
Dormont J → Brivet F, et al. 183
Douglas I → Burton NK, et al. 90
Drings P, Abel U, Bülzebruck H, Stiefel P, Kleckow M, Manke H-G: Experience with ifosfamide combination (etoposide or DDP) in non-small cell lung cancer S 34
Drings P → Havemann K, et al. S 40
Dubois J, Atassi G, Hanocq M, Abikhalil F: Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration 226
Dumas M → Gislain C de, et al. 276

Egorin MJ → Tchekmedyian NS, et al. 33
Einhorn LH, Loehrer PJ: Ifosfamide chemotherapy for pancreatic carcinoma S 51
Einhorn LH: VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer S 45
Erkelens CAM → Boven E, et al. 124
Escousse A → Gislain C de, et al. 276
Esparza L → Holmes FA, et al. 157
Evans DP, Meyn RE, Tomasovic SP: Survival of rat mammary tumor cell clones and DNA strand damage following adriamycin treatment 137
Evans J → Burton NK, et al. 90

Fanucchi MP → Sternberg CN, et al. 265
Farquhar DF → Allan SG, et al. 86
Farrar D → Perren TJ, et al. 39
Faure F → Malet-Martino M-C, et al. 5
Favalli L → Monti E, et al. 289
Fildermann AE → Teicher BA, et al. 213
Fisher C → Wiltshaw E, et al. S 10
Flentje D → Flentje M, et al. 232
Flentje M, Flentje D, Schlag P: Comparison of 5-FU versus FUDR activity in human colorectal cancer using an in vitro clonogenic assay (HTCA) 223
Fleisher M → Sternberg CN, et al. 265
Flokkmann A → Fossa SD, et al. 252
Foote SE → Paxton JW, et al. 208
Fosså SD → Hall KS, et al. 74
Fossa SD, Flokkmann A, Heier M, Aas M, Moe B, Heintz R, Linder-Ciccolunghi S: Phase I/II tolerability/pharmacokinetic study with one-hour intravenous infusion of doxifluiridine (5'-dFUrd) 3 g/m² VS 5 g/m² QD × 5 per month 252
Francher DM → Catino JJ, et al. 1
Franks CR → Cantwell BMJ, et al. 286

Gad-El-Mawla N: Ifosfamide in advanced pancreatic cancer: A 5-year experience S 55
Gale GR → Hynes JB, et al. 231
Gallagher C → Coleman RE, et al. 280
Ganesan TS → Richards MA, et al. 51
Garner P → Sriskandan K, et al. 63
Gasparini M: High dose ifosfamide alone and in combination for solid malignancies in childhood S 18
Gez E → Sulkes A, et al. 162
Gislain C de, Dumas M, Athis P d', Lautissier J-L, Escousse A, Guerrin J: Urinary β2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide 276
Glatte P → Osieka R, et al. 198
Goldberg J → Preisler HD, et al. 257
Goren MP, Wright RK, Horowitz ME: Cumulative renal tubular damage associated with cisplatin nephrotoxicity 69
Gottlieb A → Preisler HD, et al. 257
Gouyette A → Brivet F, et al. 183
Graham J → Kerr DJ, et al. 239
Gregorio MW De, Lum BL, Holleran WM, Wilbur BJ, Sikic BI: Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group 235
Gropp C → Havemann K, et al. S 40
Grotzinger KR → Louie KG, et al. 153
Grunwald H → Preisler HD, et al. 257
Günther A → Šonka J, et al. 83
Guerrin J → Gislain C de, et al. 276

Haanen C → Speth PAJ, et al. 78
Hählen K → Sonneveld P, et al. 111
Hall KS, Fosså SD, Aas M: High-dose *cis*-platinum combination chemotherapy in advanced nonseminomatous malignant germ cell tumours with emphasis on nephrotoxicity 74
Hamilton TC → Louie KG, et al. 153
Hande KR → Brenner DE, et al. 219
Hanocq M → Dubois J, et al. 226
Hans K → Havemann K, et al. S 40
Harland SJ → Mbidde EK, et al. 284
Harmer C → Wiltshaw E, et al. S 10
Harper PG → Colemann RE, et al. 280
Harris AL → Cantwell BMJ, et al. S 29
Harris AL → Cantwell BMJ, et al. 286
Harrison DJ → Allan SG, et al. 86
Hartlapp JH, Münch HJ, Illinger HJ, Wolter H, Jensen JC: Alternatives to CYVADIC combination therapy of soft tissue sarcomas S 20
Havemann K, Gropp C, Klapsing J, Viktor N, Holle R, Drings P, Manke H-G, Hans K, Schroeder M, Heim M: Two randomised trials for alternating polychemotherapy of small cell lung cancer S 40
Heier M → Fossa SD, et al. 252
Heim M → Havemann K, et al. S 40
Heintz R → Fossa SD, et al. 252
Hendry J → Molineux G, et al. 11
Hendry WF → Waxman JH, et al. 174
Herdrich K → Brade W, et al. S 1
Hersh EM → Rosenblum MG, et al. 243
Heston WDW → Scher HI, et al. 24
Hilton A → Thatcher N, et al. S 30
Holder G → Perren TJ, et al. 39
Hollande E → Malet-Martino M-C, et al. 5
Hollander P → Scher HI, et al. 24
Hollander P → Sternberg CN, et al. 265
Holle R → Havemann K, et al. S 40
Holleran WM → Gregorio MW De, et al. 235
Holmes FA, Esparza L, Yap HY, Buzdar AU, Blumenschein GR,

Hortobagyi GN: A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer 157
Horowitz ME → Goren MP, et al. 69
Hortobagyi GN → Homes FA, et al. 157
Hortobagyi GN → Rosenblum MG 247
Huffman JL Jr. → Sternberg CN, et al. 265
Humblet Y → Ceulemans F, et al. 44
Hynes JB, Smith AB, Gale GR: Effects of 5,8-dideazaisopteroylglutamate (IAHQ) on L1210 leukemia in mice when given alone and in combination with methotrexate, probenecid, or verapamil 231

Illinger HJ → Hartlapp JH, et al. S 20
Isacson R → Sulkes A, et al. 162

Jensen JC → Hartlapp JH, et al. S 20
Jolivet J → Bardakji Z, et al. 140

Kaplan RS → Tchekmedyian NS, et al. 33
Kaye SB → Kerr DJ, et al. 239
Keating M → Danhauser L, et al. 145
Kerr DJ, Graham J, Cummings J, Morrison JG, Thompson GG, Brodie MJ, Kaye SB: The effect of verapamil on the pharmacokinetics of adriamycin 239
Khokhar AR → Lautersztain J, et al. 93
Klapsing J → Havemann K, et al. S 40
Klein HO, Wickramanayake PD, Coerper C, Christian E: Treatment of advanced soft tissue and osteogenic sarcomas with continuous infusion of ifosfamide and mesna S 19
Kleckow M → Drings P, et al. S 34
Klein I → Vijgh WJF van der, et al. 129
Kraker J de, Voute PA: The role of ifosfamide in paediatric soft tissue sarcomas S 23
Kvinnsland S → Lundgren S, et al. 270

Langelier Y → Bardakji Z, et al. 140
Larson R → Preisler HD, et al. 257
Lautersztain J, Perez-Soler R, Khokhar AR, Newman RA, Lopez-Berestein G: Pharmacokinetics and tissue distribution of liposome-encapsulated *cis*-bis-*N*-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II) 93
Lautissier J-L → Gislain C de, et al. 276
Lazo JS → Teicher BA, et al. 213
Leonard RCF → Allan SG, et al. 86
Leyland-Jones B → Weiss RB, et al. 185
Linder-Ciccolunghi S → Fossa SD, et al. 252
Linssen PCM → Speth PAJ, et al. 78
Lipton A, Morris ID: Calcium antagonism by the antioestrogen tamoxifen 17
Lister TA → Burton NK, et al. 90
Lister TA → Dhaliwal HS, et al. 59
Lister TA → Richards MA, et al. 51
Loehrer PJ → Einhorn LH S 51
Lopez-Berestein G → Lautersztain J, et al. 93
Louie KG, Hamilton TC, Behrens BC, Grotzinger KR, McKoy WM, Myers CE, Young RC, Ozols RF: Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma 153
Loynds P → Wagstaff J, et al. 54
Lum BL → Gregorio MW De, et al. 235
Lundgren S, Kvinnsland S, Utaaker E, Bakke O, Ueland PM: Effect of oral high-dose progestins on the disposition of antipyrine, digitoxin, and warfarin in patients with advanced breast cancer 270
Lynch SS → Perren TJ, et al. 39

Magill PJ → Waxman JH, et al. 174
Magrath I, Sandlund J, Raynor A, Rosenberg S, Arasi V, Miser J: A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people S 25
Malet-Martino M-C, Faure F, Vialaneix J-P, Palevody C, Hollande E, Martino R: Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma 5
Malpas JS → Dhaliwal HS, et al. 59
Man A → Waxman JH, et al. 174
Man T → Richards MA, et al. 51
Manke H-G → Havemann K, et al. S 40
Manke H-G → Drings P, et al. S 34
Margison JM → Cerny T, et al. 261
Martin-Jimenez M, Diaz-Rubio E: Clinical evaluation of the simultaneous blockade of the dopamine D-2, Histamine H-1, and muscarinic cholinergic receptors in cancer chemotherapy-induced emesis: Results of a controlled trial 168
Martino R → Malet-Martino M-C, et al. 5
Mbidde EK, Harland SJ, Calvert AH, Smith IE: Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma 284
McKinna A → Wiltshaw E, et al. S 10
McKoy WM → Louie KG, et al. 153
McVie JG → Belle SJP van, et al. 27
Melamed M → Sternberg CN, et al. 265
Merrill WW → Teicher BA, et al. 213
Meyn RE → Evans DP, et al. 137
Minotti V → Roila F, et al. 88
Miser J → Magrath I, et al. S 25
Moe B → Fossa SD, et al. 252
Molineux G, Xu C, Hendry J, Testa NG: A cellular analysis of long-term haematopoietic damage in mice after repeated treatment with cyclophosphamide 11
Monti E, Piccinini F, Villani F, Favalli L: Myocardial contractility and heart pharmacokinetics of adriamycin following a single administration in rat 289
Morgan DAL: Efficacy and tolerability of vindesine in the treatment of small-cell lung cancer. A phase II study 172
Morris ID → Lipton A 17
Morrison JG → Kerr DJ, et al. 239
Mouridsen H → Dombernowsky P, et al. S 17
Mouridsen HT → Bramwell VHC, et al. S 13
Münch HJ → Hartlapp JH, et al. S 20
Myers CE → Louie KG, et al. 153

Nauta MM → Boven E, et al. 124
Newman RA → Lautersztain J, et al. 93
Niedzwiecki D → Scher HI, et al. 24
Nomura S → Tomita K, et al. 133
Nooter K → Sonneveld P, et al. 111

Oliver RTD → Waxman JH, et al. 174
Oosterom AT van: Concluding remarks S 57
Oosterom AT van → Belle SJP van, et al. 27
Oosterom AT van → Bramwell VHC, et al. S 13
Oosterom AT van → Dombernowsky P, et al. S 17
Osborne R → Coleman RE, et al. 280
Osieka R, Seeber S, Pannenbäcker R, Soll D, Glatte P, Schmidt CG: Enhancement of etoposide-induced cytotoxicity by cyclosporin A 198
Ozols RF → Louie KG, et al. 153

Palevody C → Malet-Martino M-C, et al. 5
Pannenbäcker R → Osieka R, et al. 198
Pannuti F → Camaggi CM, et al. 47
Parodi MT → Tonini GP, et al. 92
Pasini A → Zunino F, et al. 180
Pavlovitch J-M → Brivet F, et al. 183
Paxton JW, Foote SE, Singh RM: The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit 208
Perez-Soler R → Lautersztain J, et al. 93
Perren TJ, Clayton RN, Blackledge G, Bailey LC, Holder G, Lynch SS, Arkell DG, Cottam J, Farrar D, Young CH: Pharmacokinetic and endocrinological parameters of a slow-release depot pre-

paration of the GnRH analogue ICI 118630 (Zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer 39
Persici P → Tonini GP, et al. 92
Pettingale KW → Sriskandan K, et al. 63
Pfeffer MR → Sulkes A, et al. 162
Piccinini F → Monti E, et al. 289
Pinedo HM → Dombernowsky P, et al. S 17
Pinedo HM → Boven E, et al. 124
Planque MM de → Belle SJP van, et al. 27
Plunkett W → Danhauser L, et al. 145
Poplin E → Tchekmedyian NS, et al. 33
Preisler HD, Raza A, Larson R, Browman G, Goldberg J, Grunwald H, Vogler R, Bennett J, Gottlieb A, Arrigo P D': Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia 257
Prentice HG → Dhaliwal HS, et al. 59

Rahman A → Thatcher N, et al. S 30
Rankin EM → Coleman RE, et al. 280
Raynor A → Magrath I, et al. S 25
Raza A → Preisler HD, et al. 257
Richards MA, Waxman JH, Man T, Ganesan TS, Barnett MJ, Wrigley PFM, Lister TA: EVA treatment for recurrent or unresponsive Hodgkin's disease 51
Rios AM → Rosenblum MG, et al. 243
Roila F, Basurto C, Minotti V, Ballatori E, Tonato M: A phase II antiemetic combination (COMD) for cisplatin-induced nausea and vomiting 88
Rose CM → Teicher BA, et al. 213
Rosenberg S → Magrath I, et al. S 25
Rosenblum MG, Rios AM, Hersh EM: Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2) 243
Rosenblum MG, Hortobagyi GN: Pharmacokinetics and tissue disposition of the biological response modifier BAY i 7433 (copovithane) in patients with cancer 247
Roussé J → Dombernowsky P, et al. S 17
Russo M → Weiss RB, et al. 185

Sandlund J → Magrath I, et al. S 25
Sandow J → Waxman JH, et al. 174
Santelli G, Valeriote F: Schedule-dependent antitumor and toxic effects of thymidine and 5-fluorouracil in AKR and L1210 leukemias 101
Santoro A → Bramwell VHC, et al. S 13
Santoro A → Dombernowsky P, et al. S 17
Sarosy G → Weiss RB, et al. 185
Savi G → Zunino F, et al. 180
Scher HI, Sternberg C, Heston WDW, Watson RC, Niedzwiecki D, Smart T, Hollander P, Yagoda A, Community Cancer Oncology Program Investigators: Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease 24
Schlag P → Flentje M, et al. 223
Schmidt CG → Osieka R, et al. 198
Schlüper HMM → Boven E, et al. 124
Schoemaker TJ → Belle SJP van, et al. 27
Schroeder M → Havemann K, et al. S 40
Schrøder H: Methotrexate pharmacokinetics in age-fractionated erythrocytes 203
Schütte J → Dombernowsky P, et al. S 17
Schultz FW → Sonneveld P, et al. 111
Schurig JE → Catino JJ, et al. 1
Seeber S → Brade W, et al. S 1
Seeber S → Osieka R, et al. 198
Shannon MS → Dhaliwal HS, et al. 59
Sikic BI → Gregorio MW De, et al. 235
Silverstone AC → Coleman RE, et al. 280
Singh RM → Paxton JW, et al. 208
Slevin ML → Coleman RE, et al. 280
Smart T → Scher HI, et al. 24
Smith AB → Hynes JB, et al. 231
Smith DB → Thatcher N, et al. S 30
Smith IE → Belle SJP van, et al. 27
Smith IE → Mbidde EK, et al. 284
Soll D → Osieka R, et al. 198
Somers R → Bramwell VHC, et al. S 13
Somers R → Dombernowsky P, et al. S 17
Šonka J, Günther A, Volm M: Decreased autolysis of dead cells in Adriamycin-resistant lines of the sarcoma 180 of mouse 83
Sonneveld P, Schultz FW, Nooter K, Hählen K: Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate 111
Souhami RL → Coleman RE, et al. 280
Speth PAJ, Linssen PCM, Beex LVAM, Boezeman JBM, Haanen C: Cellular and plasma pharmacokinetics of weekly 20-mg 4'-epi-adriamycin bolus injection in patients with advanced breast carcinoma 78
Sriskandan K, Garner P, Watkinson J, Pettingale KW, Brinkley D, Calman FMB, Tee DEH: A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer 63
Sternberg C → Scher HI, et al. 24
Sternberg CN, Yagoda A, Bander NH, Whitmore WF Jr, Huffman JL, Fleisher M, Melamed M, Fanucchi MP, Hollander P, Vaughan ED Jr: Phase I/II trial of intravesical methotrexate for superficial bladder tumors 265
Steward WP → Thatcher N, et al. S 30
Stewart W → Dombernowsky P, et al. S 17
Stiefel P → Drings P, et al. S 34
Strocchi E → Camaggi CM, et al. 47
Sulkes A, Gez E, Pfeffer MR, Catane R, Isacson R, Biran S: Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer 162
Sylvester R → Bramwell VHC, et al. S 13
Sylvester R → Dombernowsky P, et al. S 17
Symann M → Ceulemans F, et al. 44

Tchekmedyian NS, Egorin MJ, Cohen BE, Kaplan RS, Poplin E, Aisner J: Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion 33
Tchernia G → Brivet F, et al. 183
Tee DEH → Sriskandan K, et al. 63
Teicher BA, Lazo JS, Merrill WW, Fildermann AE, Rose CM: Effect of Fluosol-DA/O_2 on the antitumor activity and pulmonary toxicity of bleomycin 213
Testa NG → Molineux G, et al. 11
Testoni F → Camaggi CM, et al. 47
Thatcher N → Cerny T, et al. 261
Thatcher N, Anderson H, Smith DB, Steward WP, Webb K, Hilton A, Rahman A: Ifosfamide by bolus as treatment for advanced non-small cell lung cancer S 30
Thomas D → Bramwell VHC, et al. S 13
Thomas D → Dombernowsky P, et al. S 17
Thompson GG → Kerr DJ, et al. 239
Tomasovic SP → Evans DP, et al. 137
Tomita K, Yokogawa A, Nomura S: Human tumor clonogenic assay in osteosarcoma for evaluation of clinical efficacy of anti-cancer drugs 133
Tonato M → Roila F, et al. 88
Tonini GP, Parodi MT, Bologna R, Persici P, Cornaglia-Ferraris P: Cisplatin induces modulation of transferrin receptor during cellular differentiation in vitro 92
Tobias JS → Coleman RE, et al. 280
Trask CW → Coleman RE, et al. 280
Trouet A → Ceulemans F, et al. 44
Tsuji H → Abe R, et al. 98

Ueland PM → Lundgren S, et al. 270
Utaaker E → Lundgren S, et al. 270

Valeriote F → Santelli G 101
Vasanthakumar G, Ahmed NK: Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells 105
Vaughan ED, Jr → Sternberg CN, et al. 265
Vialaneix J-P → Malet-Martino M-C, et al. 5
Vijgh WJF van der, Klein I: Protein binding of five platinum compounds. Comparison of two ultrafiltration systems 129
Viktor N → Havemann K, et al. S 40
Villani F → Monti E, et al. 289
Vogler R → Preisler HD, et al. 257
Volm M → Šonka J, et al. 83
Voute PA → Kraker J de S 23

Wagstaff J, Loynds P, Crowther D: A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma 54
Watkinson J → Sriskandan K, et al. 63
Watson RC → Scher HI, et al. 24
Waxman JH → Richards MA, et al. 51
Waxman JH, Sandow J, Man A, Barnett MJ, Hendry WF, Besser GM, Oliver RTD, Magill PJ: The first clinical use of depot buserelin for advanced prostatic carcinoma 174
Webb K → Thatcher N, et al. S 30
Weiss RB, Sarosy G, Clagett-Carr K, Russo M, Leyland-Jones B: Anthracycline analogs: The past, present, and future 185
Westbury G → Wiltshaw E, et al. S 10
Whitmore WF, Jr → Sternberg CN, et al. 265
Wickramanayake PD → Klein HO, et al. S 19
Wilbur BJ → Gregorio MW De, et al. 235
Wilkinson PM → Cerny T, et al. 261
Williams PD → Bregmann CL 117
Wiltshaw E → Coleman RE, et al. 280
Wiltshaw E, Westbury G, Harmer C, McKinna A, Fisher C: Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma S 10
Wolter H → Hartlapp JH, et al. S 20
Wright RK → Goren MP, et al. 69
Wrigley PFM → Richards MA, et al. 51

Xu C → Molineux G, et al. 11

Yagoda A → Scher HI, et al. 24
Yagoda A → Sternberg CN, et al. 265
Yap HY → Holmes FA, et al. 157
Yokogawa A → Tomita K, et al. 133
Young CH → Perren TJ, et al. 39
Young RC → Louie KG, et al. 153

Zunino F, Savi G, Pasini A: Synthesis and antitumor activity of a platinum (II)-doxorubicin complex 180

Subject index of volume 18

Aclacinomycin A 153
Acute leukemia 59
Acute lymphoblastic leukemia 111
Adriamycin 162, 239, 289, S 10, S 17
4'-epi-Adriamycin 78
Adriamycin(doxorubicin HCl) 137
Advanced pancreatic cancer S 55
9-ß-D-Arabinofuranosyl-2-fluoroadenine 145
m-AMSA 59
Amsacrine 208
Anthracycline analogs 185
Anti-emesis 86
Antiemetic therapy 88
Autolysis 83

Biological response modifier 247
Bisantrene 157
Bladder tumors 265
Bleomycin 213
Bolus S 30
Bone marrow 111
--, incorporation 203
Breast cancer 162, 270
- -, metastatic 157
Bronchal carcinoma 261

Calcium antagonism 17
Calmodulin 21
Cancer chemotherapy 86
Carboplatin 117, 235, 284
Carcinoma of the cervix 280
Cardiotoxicity 289
Cell cultures 5
Cellular concentrations 78
Chemosensitization 140, 198
Chemotherapy-induced emesis 168
Chlorambucil 176
Cimetidine 219
Cisdiamminedichloroplatinum 276
Cisplatin 1, 88, S 45
Cisplatin nephrotoxicity 69
Clonogenic assay 133
Colorectal cancer 140, 223
Combination chemotherapy 27, S 20, S 34
Cyclophosphamide 11, 33, S 1
- vs. ifosfamide S 13
Cytosine-arabinoside 59, 257
Cytotoxicity 1

Daunorubicin 105
Dexamethasone 86
Depot buserelin 174
cis-Diamminedichloroplatinum (II) 98
5,8-Dideazaisopterylglutamate (IAHQ) 231
Discontinuous Percoll gradients 203
Dose schedule 157
Doxorubicin 219
Drug drapping 83
Drug interaction 270

Elimination profiles 252
Epirubicin 47
Etoposide 24
EVA treatment 51

Fluorine-19NMR 5
Fluoropyrimidine metabolism 5
5-Fluorouracil 101, 140, 223
Fluosol-DA 213
5-FU 223
5'-dFUrd 252
Furosemide 276

Gonadotropin releasing
hormone analogue 39

Haematopoiesis 11
Hemodialysis 183
Hexamethylmelamine 124, 226
High-dose cis-platinum 74
Hodgkin's disease 51
HPLC 261

HTCA 223
Human pancreatic and colon
adenocarcinoma 5
Hydroxymethotrexate 111

Ifosfamide 261, 280, S 1, S 10, S 13,
S 17, S 19, S 20, S 23, S 25, S 30,
S 34, S 45, S 51, S 55
Ifosfamide, high dose S 18
Ifosfamide/mesna S 29
Infusion 33
Interferon-2 54
Interferon-gamma 63

Leukemic cells 105
Liposomal platinum 93
Low dose 78

Malignant germ cell tumours 74
Malignant mesothelioma 284
6-Mercaptopurine 90
Mesna S10, S17, S19
Methotrexate 111, 265
Metoclopramide 1
Metronidazole 140
Microsomal monooxigenases 270
Mitomycin C 162
Mitoxantrone 27
5-Monophosphate (F-ara-AMP) 145

Nephrotoxicity 276
Neurotoxicity 252
Non-Hodgkin's lymphoma 54
Nonlymphocytic leukemia 74, 257
Non-small cell lung cancer S34

Osteogenic sarcoma S 19
Osteosarcoma 133
Ovarian cancer 124
Overdose 183

Paediatric soft tissue sarcomas S23
Pancreatic carcinoma S 51
Pharmacokinetics 27, 39, 47, 78, 93, 140, 153,
219, 226, 235, 239, 247,
Pharmacokinetics/MVE-2 243
PHA stimulation assay 98
Phenothiazines 21
cis-Platinum 183
Platinum analogues 286
Platinum compounds 129
Platinum(II)-doxorubicin complex 180
Pleural mesothelioma 286
Polychemotherapy S 40
Progestins 270
Prostatic cancer 24, 39
Prostatic carcinoma 174
Protein binding 129

Recurrent sarcomas S 25
Resistance 83
Reticulocyte enrichment 203

Small cell lung cancer S 29, S 40
Sodium thiosulfate 1, 98
Solid malignancies S 18
Soft tissue sarcoma S 10, S 13, S 17, S 19, S 20
Storage 176

Tamoxifen 17, 21
Testicular cancer S 45
Tissue pharmacokinetics 289
Tobramycin nephrotoxicity 117
Tolerability 252
Toxicity 63
Trimelamon 124

Verapamil 239
Vinblastine 162
Vinblastine tryptophan ester 44
Vindesine 172
VP16 S 45

Xenografts 124